Market capitalization of biopharmaceutical companies exceeds KRW 1 trillion

It was observed the average R&D investment ratio of listed biopharmaceutical companies to sales exceeded 20%.

The phenomenon seems biopharmaceutical ventures have to spend an enormous amount of R&D expenses, but have relatively weaker structures externally.

In fact, there were approximately 5 biopharmaceutical companies which have recorded less than KRW 10 billion sales by the 3^rd quarter thi...